The 503B Loophole Closes: Why the FDA is Moving to Exclude GLP-1s from Bulk Compounding
On April 30, 2026, the FDA proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As legitimate compounding pathways narrow, independent analytical testing becomes the only reliable defense against substandard supply.
98% Pure. So What Is the Other 2%?
98% pure is the most common claim in the peptide industry. But what is the other 2%? A peptide impurity investigation.
The “Wild West” Week: What 6 Major Outlets Got Right — and Wrong — About Peptide Quality
Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.
The “Wild West” Week: What 6 Major Outlets Got Right — and Wrong — About Peptide Quality
Six major publications ran peptide safety stories in five days. We read all of them, traced their claims back to the data, and found a more complicated picture than any single headline captured.